Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Revenue projections:

Revenue projections for MRNA
Revenue projections for MRNA

MRNA's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 2.295000
forwardPE -12.934327
debtToEquity 19.036000
earningsGrowth 0.000000
revenueGrowth 0.021000
grossMargins -0.660230
operatingMargins -5.579310
trailingEps -7.980000
forwardEps -4.895500

MRNA's current ratio being 2.295 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, MRNA can easily cover its immediate liabilities, reflecting solid financial health.
MRNA's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests MRNA maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.

Price projections:

Price projections for MRNA
Price projections for MRNA

MRNA's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

Insider Transactions for MRNA
Insider Transactions for MRNA


Moderna, Inc. had 12 sell transactions, while the market price was at 46.556666692097984 per share.Throughout the period under consideration, no sell transactions were recorded.The trend of more buys compared to sells around Moderna, Inc.'s current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for MRNA
Recommendations trend for MRNA


Analysts have shown a buy bias for MRNA, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to MRNA, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.